Business Context and Reporting Period
Company: ImmuCell Corp.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 1998
Business Overview: ImmuCell is a biotechnology company focused on developing passive antibody products for human and animal health, as well as diagnostic technologies. Key products include "First Defense" and the "Kamar Heatmount Detector." The company operates joint ventures for lactoferrin production and water diagnostics.
Key Financial Metrics
| Metric | Six Months Ended June 30, 1998 | Six Months Ended June 30, 1997 |
|---|---|---|
| Total Revenues | $2,191,422 | $2,147,755 |
| Net Profit (Loss) | $139,028 | $(52,466) |
| Net Profit Per Share (Diluted) | $0.05 | $(0.02) |
| Operating Cash Flow | $439,194 | $33,199 |
| Cash and Equivalents (Ending) | $1,352,379 | $931,573 |
| Total Assets | $3,295,584 | $3,231,050 |
| Total Debt (Long-term + Current) | $478,638 | $570,021 |
| Stockholders' Equity | $2,489,142 | $2,329,508 |
Gross Margin: 55% for the six-month period ended June 30, 1998 (consistent with the prior year).
Material Changes vs. Prior Period
- Profitability Turnaround: The company reported a net profit of $139,028 for the six months ended June 30, 1998, compared to a net loss of $52,466 in the same period in 1997. This was driven by reduced operating expenses and increased grant income.
- Revenue Growth: Total revenues increased by approximately 2% year-over-year. Product sales rose 4% to $2.13 million, while grant income increased significantly to $62,772 (up from $26,881). Technology licensing income of $75,000 recorded in 1997 did not recur in 1998.
- Expense Reduction: Research and development (R&D) expenses decreased by 22% ($113,000) to $411,861. Sales and marketing expenses declined by 7% to $417,639.
- Debt Refinancing: In May 1998, the company refinanced its debt obligations. It secured a new $480,000 mortgage loan at a fixed rate of 8.62% to repay all outstanding bank debt, reducing total debt levels and altering the maturity profile.
- Liquidity Improvement: Cash and cash equivalents increased by $331,055, and net working capital improved by $300,000 compared to December 31, 1997.
Outlook, Risks, and Management Commentary
- Future Losses Expected: Management explicitly states that the company expects to incur operating losses in the future as it aggressively invests in R&D to develop new products and demonstrate efficacy in clinical trials.
- Strategic Focus: The strategy involves developing products for veterinarians and farmers (animal health) and pursuing corporate partners to fund continued development in exchange for marketing rights.
- Capital Resources: Management believes current capital resources are sufficient to meet working capital requirements for the next twelve months. A $710,000 Phase II Small Business Innovation Research grant obtained in September 1997 has approximately $447,000 remaining as of July 1, 1998.
- Joint Ventures: Operating activity from joint ventures (AgriCell and Clearwater Diagnostics) was not material to date, though AgriCell has initiated limited sales of lactoferrin.
- Risks: The company relies on external funding and partnerships for future growth. There are no material legal proceedings or defaults on senior securities reported.
Investor Verification Checklist
- Sustainability of Profitability: Verify if the net profit for the six-month period is sustainable given management's expectation of future operating losses due to R&D investments.
- Grant Dependency: Assess the reliance on the remaining $447,000 from the SBIR grant and the timeline for its utilization.
- Debt Service: Review the terms of the new $480,000 mortgage, specifically the balloon payment structure due in 2003 and the interest rate reset option.
- Product Concentration: Confirm that 95-96% of product sales continue to rely on "First Defense" and the "Kamar Heatmount Detector," creating concentration risk.
- Joint Venture Progress: Monitor the commercial progress of AgriCell (lactoferrin) and Clearwater Diagnostics (water testing) to determine if they will become material revenue sources.